Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neogen Corporation SEC filings document material events for an operating company focused on food safety and animal safety products. Recent 8-K filings cover quarterly results and financial condition, Regulation FD disclosures related to Petrifilm manufacturing validation, and exhibits containing earnings releases and business updates.
The company’s filings also record governance and leadership matters, including executive appointments and departures, compensatory arrangements, board committee assignments, annual meeting voting results, executive compensation votes, and auditor ratification. These disclosures provide formal records of Neogen’s public-company reporting, operating updates, governance structure and shareholder matters.
NEOGEN CORP filed an insider ownership report for Chief Legal Officer Stacey Jennifer Evans. The filing lists her as an officer reporting person but shows no reported share transactions or derivative positions, and no current holdings entries, in the summarized data provided.
Neogen Corporation reported fiscal third quarter 2026 revenue of $211.2 million, down 4.4% from $221.0 million a year earlier, and posted a net loss of $17.0 million, or $(0.08) per diluted share. Food Safety sales grew 2.6% to $156.7 million, while Animal Safety revenue fell 20.1% to $54.5 million due to third‑party supplier issues.
On an adjusted basis, Neogen generated Adjusted EBITDA of $48.2 million with a 22.8% margin and Adjusted Net Income of $19.4 million, or $0.09 per share. The company raised its fiscal 2026 revenue outlook to $857–$860 million and maintained Adjusted EBITDA guidance of about $175 million.
Neogen also agreed to sell its global Genomics business to Zoetis for $160.0 million, expecting roughly $140.0 million of net cash proceeds to support a targeted net debt‑to‑Adjusted EBITDA ratio of less than three times by the end of calendar 2026. The Petrifilm manufacturing transition remains on track for completion by November 2026.
Neogen Corporation reported a leadership change in its legal function. The company announced that its Chief Legal and Administrative Officer, Amy Rocklin, will leave the company. Her departure is effective March 31, 2026, following the company’s announcement on March 30, 2026.
The Vanguard Group filed Amendment No. 15 to a Schedule 13G/A reporting 0 shares of Neogen Corp, representing 0% beneficial ownership. The amendment notes an internal realignment on January 12, 2026 under SEC Release No. 34-39538 that led certain Vanguard subsidiaries and business divisions to report holdings separately. The filing states those subsidiaries pursue the same investment strategies and that The Vanguard Group, Inc. no longer is deemed to beneficially own securities reported by those entities. The form lists the issuer address as 620 Lesher Place, Lansing, MI, and is signed by Ashley Grim on 03/27/2026.
Neogen Corporation’s common stock is reported as being beneficially owned by Gates Capital Management entities and Jeffrey L. Gates, who together report 8,385,534 shares, or 3.9% of the company’s common stock. All of these shares are shown with shared voting and shared dispositive power, and none with sole authority.
The ownership percentage is calculated using 217,525,981 shares outstanding as of November 30, 2025, as disclosed in Neogen’s Form 10-Q for that period. The reporting parties state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Neogen.
Neogen Corp’s CEO, Nassif Mikheal, reported an indirect open‑market purchase of company stock associated with his son. On February 17, 2026, 23 shares of Neogen common stock were bought at $10.94 per share. Following this trade, 704 shares are reported as indirectly owned "by son." A footnote states that Mikheal disclaims beneficial ownership of these securities, meaning he does not concede that he is their beneficial owner for regulatory or any other purpose.
Neogen Corporation filed a Form 4 detailing small stock purchases made in an account held by the CEO’s son. On 01/26/2026, the son purchased 25 shares of common stock at $9.855 per share, and on 02/02/2026, 24 shares at $9.9997 per share. After these trades, that account held 681 shares. The filing states that CEO Nassif Mikheal reports these holdings indirectly and expressly disclaims beneficial ownership of these securities.
Neogen Corporation reported that a senior vice president received new equity awards on 01/07/2026. The officer was granted 261,210 stock options with a conversion price of $7.38 per share, exercisable until 01/07/2036, covering 261,210 shares of common stock.
In addition, the officer acquired 50,813 shares of common stock linked to options and RSUs and another 50,813 shares tied to PSUs, both at a reference price of $7.38 per share. The options and RSUs vest in three equal annual installments, while the PSUs vest in full at the end of the three-year anniversary of the grant.
Neogen Corporation Senior Vice President Tamara A. Ranalli reported new equity awards. On January 7, 2026, she was granted 130,605 options to acquire Neogen common stock at an exercise price of $7.38 per share, leaving her with 130,605 derivative securities beneficially owned directly. The same day she also acquired 50,813 shares of common stock at a stated price of $7.38 per share, bringing her directly held common stock to 50,813 shares. According to the filing, the options and restricted stock units vest in three equal annual installments on each of the first three anniversaries of the grant date.